



(12) **EUROPEAN PATENT APPLICATION**

(88) Date of publication A3: **07.01.2004 Bulletin 2004/02** (51) Int Cl.7: **C12Q 1/68, G01N 33/50**

(43) Date of publication A2: **15.10.2003 Bulletin 2003/42**

(21) Application number: **03006128.7**

(22) Date of filing: **18.03.2003**

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
 Designated Extension States:
AL LT LV MK

(72) Inventors:
 • **Müller, Dieter**
20249 Hamburg (DE)
 • **Mukhopadhyay, Amal K.**
22523 Hamburg (DE)
 • **Wessels, Judith**
20255 Hamburg (DE)

(30) Priority: **18.03.2002 DE 10211915**
18.03.2002 US 365371 P

(74) Representative: **UEXKÜLL & STOLBERG**
Patentanwälte
Beselerstrasse 4
22607 Hamburg (DE)

(71) Applicant: **Jenapharm GmbH & Co. KG**
07745 Jena (DE)

(54) **Methods of identifying a pharmaceutically active compound for the treatment of a condition caused by altered expression of the insulin receptor**

(57) The present invention relates to a method of identifying a pharmaceutically active compound for the treatment of a condition caused by altered expression of the insulin receptor. The invention further relates to a

method of diagnosing a condition in a mammal using an *in-vitro* assay. The invention also relates to a method for preparing a pharmaceutical composition for the treatment of a condition caused by altered expression of the insulin receptor.




Fig. 1



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 03 00 6128 shall be considered, for the purposes of subsequent proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	WO 01 28539 A (GLAXO GROUP LTD ; MCCARTHY LINDA CATHERINE (GB); PURVIS IAN JAMES () 26 April 2001 (2001-04-26) * claims 1,8-10 * * page 4, line 27 - line 31 * * page 6, line 18 - line 15 * ---	1-32	C12Q1/68 G01N33/50
Y	WO 02 17963 A (PFIZER LTD ; MAW GRAHAM NIGEL (GB); WAYMAN CHRISTOPHER PETER (GB);) 7 March 2002 (2002-03-07) * claims 26,27 * * page 79, line 21 - line 23 * ---	1-32	
A	MOLLER & FLIER: "insulin resistance-mechanisms, syndromes, and implications" NEW ENG J MED, vol. 325, no. 13, 26 September 1991 (1991-09-26), pages 938-948, XP000802449 * the whole document * ----- -/--		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)
			C12Q
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>Although claims 1-13 and 20-32 are directed to a diagnostic method practised on the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		18 November 2003	Bellmann, A
CATEGORY OF CITED DOCUMENTS		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ----- & : member of the same patent family, corresponding document	
X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document			

EPO FORM 1503 03 82 (P04C07)



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 03 00 6128

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	BENECKE H. ET AL.: "ALTERNATIVELY SPLICED VARIANTS OF THE INSULIN RECEPTOR PROTEIN" J CLIN INVEST, vo1. 89, June 1992 (1992-06), pages 2066-2070, XP008024491 ---		
A	SESTI G ET AL: "MOLECULAR MECHANISM OF INSULIN RESISTANCE IN TYPE 2 DIABETES MELLITUS: ROLE OF THE INSULIN RECEPTOR VARIANT FORMS" DIABETES/METABOLISM RESEARCH AND REVIEWS, WILEY, LONDON,, GB, vo1. 17, no. 5, September 2001 (2001-09), pages 363-373, XP009003380 ISSN: 1520-7552 * the whole document * -----		
			TECHNICAL FIELDS SEARCHED (Int.Cl.7)

EPO FORM 1503 03.82 (P04C10)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 03 00 6128

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

18-11-2003

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0128539 A	26-04-2001	AU 1036801 A WO 0128539 A2	30-04-2001 26-04-2001
WO 0217963 A	07-03-2002	AU 8237701 A CA 2420852 A1 EP 1313507 A2 WO 0217963 A2	13-03-2002 07-03-2002 28-05-2003 07-03-2002

EPC FORM P0459

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

专利名称(译)	鉴定药理学活性化合物的方法，所述药理学活性化合物用于治疗由胰岛素受体的表达改变引起的病症		
公开(公告)号	EP1352972A3	公开(公告)日	2004-01-07
申请号	EP2003006128	申请日	2003-03-18
申请(专利权)人(译)	JENAPHARM GMBH & CO.KG		
当前申请(专利权)人(译)	JENAPHARM GMBH & CO.KG		
[标]发明人	MULLER DIETER MUKHOPADHYAY AMAL K WESSELS JUDITH		
发明人	MÜLLER, DIETER MUKHOPADHYAY, AMAL K. WESSELS, JUDITH		
IPC分类号	G01N33/50 A61K45/00 A61P15/10 A61P43/00 C12N15/09 C12Q1/02 C12Q1/68 C12R1/91 G01N33/15 G01N33/53 G01N33/566		
CPC分类号	A61P15/10 C12Q1/6883 C12Q2600/158		
代理机构(译)	UEXKÜLL & STOLBERG		
优先权	10211915 2002-03-18 DE 60/365371 2002-03-18 US		
其他公开文献	EP1352972A2		
外部链接	Espacenet		

摘要(译)

本发明涉及鉴定药理学活性化合物的方法，所述药理学活性化合物用于治疗由胰岛素受体的表达改变引起的病症。本发明还涉及使用体外测定法诊断哺乳动物病症的方法。本发明还涉及制备药物组合物的方法，所述药物组合物用于治疗由胰岛素受体的表达改变引起的病症。




Fig. 1